Dashboard
Manage Tickers

CRDL Cardiol Therapeutics Inc.

Nasdaq cardiolrx.com


$ 1.11 $ 0.00 (0 %)    

Friday, 31-Oct-2025 10:21:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.22 $ -0.78 (-0.12 %)
DIA $ 476.18 $ 0.32 (0.07 %)
SPY $ 684.35 $ -0.76 (-0.11 %)
TLT $ 90.47 $ -0.09 (-0.1 %)
GLD $ 369.23 $ -1.19 (-0.32 %)
$ 1.1
$ 1.09
$ 1.11 x 1,403
$ 1.12 x 2,000
$ 1.09 - $ 1.12
$ 0.77 - $ 2.24
368,038
na
90.87M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cardiol-therapeutics-to-present-new-data-from-archer-trial-highlighting-magnitude-of-reduction-in-lv-mass-and-read-through-to-heart-failure-at-cardiology-conference-in-november
Cardiol Therapeutics To Present New Data F...
10/21/2025 11:30:19

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a plan...

trading-halt-halt-status-updated-at-50000-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 5:00:...
10/17/2025 21:00:08

cardiol-therapeutics-completes-11m-private-placement-selling-11m-units-at-1unit-says-maveric-phase-iii-pivotal-trial-of-orphan-drug-candidate-cardiolrx-in-recurrent-pericarditis-is-fully-funded-through-to-a-planned-nda-submission-with-the-fda-data-from-the-archer-trial-to-be-presented-at-a-cardiology-conference-in-november-2025
Cardiol Therapeutics Completes $11M Privat...
10/17/2025 20:38:33

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a plan...

trading-halt-halted-at-41436-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:14:36 p.m. ET - ...
10/17/2025 20:14:40

cardiol-therapeutics-reports-compelling-archer-trial-results-supporting-advancement-of-cardiolrx-and-crd-38-in-myocarditis-and-heart-failure
Cardiol Therapeutics Reports Compelling AR...
08/06/2025 11:29:47

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) fa...

cardiol-locks-key-trial-data-as-it-advances-new-treatment-for-dangerous-heart-inflammation
Cardiol Locks Key Trial Data as It Advance...
07/22/2025 11:33:47

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences...

this-visa-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday
This Visa Analyst Begins Coverage On A Bul...
06/02/2025 13:12:47

hc-wainwright--co-initiates-coverage-on-cardiol-therapeutics-with-buy-rating-announces-price-target-of-9
HC Wainwright & Co. Initiates Coverage On ...
06/02/2025 10:32:25

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating an...

hc-wainwright--co-initiates-coverage-on-cardiol-therapeutics-with-buy-rating-announces-price-target-of-9
HC Wainwright & Co. Initiates Coverage On ...
06/02/2025 10:32:25

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating an...

hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Card...
04/16/2025 16:11:33

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

cardiol-therapeutics-enrolls-first-patient-in-pivotal-phase-iii-maveric-trial-evaluating-cardiolrx-for-prevention-of-recurrent-pericarditis
Cardiol Therapeutics Enrolls First Patient...
04/16/2025 11:32:11

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been random...

hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Card...
04/07/2025 17:12:12

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Card...
02/24/2025 12:25:04

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Card...
12/18/2024 11:55:35

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Card...
11/20/2024 12:02:23

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

cbd-based-drug-reduces-pericarditis-pain-and-inflammation-shows-new-clinical-study
CBD-Based Drug Reduces Pericarditis Pain A...
11/19/2024 19:24:47

cardiol-therapeutics-presents-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis-presented-at-the-aha-scientific-sessions-2024-marked-and-rapid-reductions-in-both-pericarditis-pain-and-inflammation-maintained-throughout-the-26-week-study
Cardiol Therapeutics' Presents Phase II MA...
11/18/2024 16:38:46

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of peric...

hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Card...
10/24/2024 11:32:36

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

cardiol-therapeutics-plans-to-expand-maveric-clinical-development-program-and-advance-cardiolrx-into-late-stage-clinical-trial
Cardiol Therapeutics Plans To Expand MAVER...
10/22/2024 10:41:52

why-cardiol-therapeutics-crdl-stock-is-down-20-today
Why Cardiol Therapeutics (CRDL) Stock Is D...
10/09/2024 14:41:56

Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION